淋巴水肿的新型及新兴治疗方法
New and Emerging Treatments for Lymphedema.
作者信息
Schaverien Mark V, Aldrich Melissa B
机构信息
Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.
Center for Molecular Imaging, Brown Institute for Molecular Medicine, UT Health, Houston, Texas.
出版信息
Semin Plast Surg. 2018 Feb;32(1):48-52. doi: 10.1055/s-0038-1632403. Epub 2018 Apr 9.
Abstract
Although nonoperative and operative treatments for lymphedema (LE) are well established, these procedures typically provide only partial relief from limb swelling, functional impairment, and the risk of cellulitis. The lack of a cure for LE, however, is due to an incomplete understanding of the underlying pathophysiological mechanisms, and current research efforts are focusing on elucidating these processes to provide new, targeted therapies for this prevalent disease for which there is no cure. This article reviews the current literature regarding the pathophysiological mechanisms that underlie LE, as well as new and emerging therapies for the condition.
摘要
尽管淋巴水肿（LE）的非手术和手术治疗方法已得到充分确立，但这些方法通常只能部分缓解肢体肿胀、功能障碍和蜂窝织炎风险。然而，LE无法治愈是由于对其潜在病理生理机制的理解不完整，目前的研究工作正集中于阐明这些过程，以便为这种尚无治愈方法的常见疾病提供新的靶向治疗。本文综述了关于LE潜在病理生理机制的当前文献，以及针对该病症的新出现的治疗方法。
相似文献
1
New and Emerging Treatments for Lymphedema.淋巴水肿的新型及新兴治疗方法
Semin Plast Surg. 2018 Feb;32(1):48-52. doi: 10.1055/s-0038-1632403. Epub 2018 Apr 9.
2
Risk factors for cellulitis in patients with lymphedema: a case-controlled study.淋巴水肿患者蜂窝织炎的风险因素：一项病例对照研究。
Lymphology. 2013 Sep;46(3):150-6.
3
Peculiar clinical features of cellulitis in peripheral lymphedema.外周性淋巴水肿中蜂窝织炎的特殊临床特征。
Lymphology. 2018;51(2):47-53.
4
Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months.乳腺癌相关淋巴水肿：发病风险在 12 个月、30 个月和 60 个月时分别增加至 12%、30%和 60%。
Lymphology. 2010 Sep;43(3):118-27.
5
Manipulative therapy of secondary lymphedema in the presence of locoregional tumors.局部区域肿瘤存在时继发性淋巴水肿的手法治疗
Cancer. 2008 Feb 15;112(4):950-4. doi: 10.1002/cncr.23242.
6
Review of current surgical treatments for lymphedema.当前淋巴水肿外科治疗方法综述。
Ann Surg Oncol. 2014 Apr;21(4):1195-201. doi: 10.1245/s10434-014-3518-8. Epub 2014 Feb 21.
7
The problem of post-breast cancer lymphedema: impact and measurement issues.乳腺癌后淋巴水肿问题：影响及测量问题
Cancer Invest. 2005;23(1):76-83.
8
Current Understanding of Pathological Mechanisms of Lymphedema.当前对淋巴水肿病理机制的认识。
Adv Wound Care (New Rochelle). 2022 Jul;11(7):361-373. doi: 10.1089/wound.2021.0041. Epub 2021 Nov 25.
9
10
Efficacy of laser CO treatment for refractory lymphedema secondary to cancer treatments.激光CO治疗癌症治疗后继发性难治性淋巴水肿的疗效。
Lasers Surg Med. 2022 Mar;54(3):337-341. doi: 10.1002/lsm.23498. Epub 2021 Nov 27.
引用本文的文献
1
Prophylactic Lymphovenous Bypass at the Time of Axillary Lymph Node Dissection Decreases Rates of Lymphedema.腋窝淋巴结清扫时进行预防性淋巴静脉分流可降低淋巴水肿的发生率。
Ann Surg Open. 2023 May 2;4(2):e278. doi: 10.1097/AS9.0000000000000278. eCollection 2023 Jun.
2
Current Understanding of Pathological Mechanisms of Lymphedema.当前对淋巴水肿病理机制的认识。
Adv Wound Care (New Rochelle). 2022 Jul;11(7):361-373. doi: 10.1089/wound.2021.0041. Epub 2021 Nov 25.
3
Exosomes derived from human umbilical cord Wharton's jelly mesenchymal stem cells ameliorate experimental lymphedema.源自人脐带华通氏胶间充质干细胞的外泌体可改善实验性淋巴水肿。
Clin Transl Med. 2021 Jul;11(7):e384. doi: 10.1002/ctm2.384.
4
Technical Challenges in "Micro" Lymph Node Identification during Vascularized Submental Lymph Node Flap Harvesting.带血管蒂颏下淋巴结瓣切取术中“微型”淋巴结识别的技术挑战
Plast Reconstr Surg Glob Open. 2020 Dec 18;8(12):e3330. doi: 10.1097/GOX.0000000000003330. eCollection 2020 Dec.
5
The Development and Treatment of Lymphatic Dysfunction in Cancer Patients and Survivors.癌症患者及幸存者淋巴功能障碍的发展与治疗
Cancers (Basel). 2020 Aug 14;12(8):2280. doi: 10.3390/cancers12082280.
6
The effects of synbiotic supplementation on serum inflammatory markers and edema volume in breast cancer survivors with lymphedema.合生元补充剂对乳腺癌淋巴水肿幸存者血清炎症标志物和水肿体积的影响。
EXCLI J. 2020 Jan 2;19:1-15. doi: 10.17179/excli2019-1876. eCollection 2020.
本文引用的文献
1
Lymphatic Dysfunction, Leukotrienes, and Lymphedema.淋巴功能障碍、白三烯与淋巴水肿
Annu Rev Physiol. 2018 Feb 10;80:49-70. doi: 10.1146/annurev-physiol-022516-034008. Epub 2017 Oct 13.
2
Regulatory T Cells Mediate Local Immunosuppression in Lymphedema.调节性 T 细胞介导淋巴水肿中的局部免疫抑制。
J Invest Dermatol. 2018 Feb;138(2):325-335. doi: 10.1016/j.jid.2017.09.011. Epub 2017 Sep 20.
3
Treatment of Breast Cancer-Related Lymphedema with Adipose-Derived Regenerative Cells and Fat Grafts: A Feasibility and Safety Study.脂肪来源再生细胞和脂肪移植治疗乳腺癌相关性淋巴水肿：一项可行性和安全性研究。
Stem Cells Transl Med. 2017 Aug;6(8):1666-1672. doi: 10.1002/sctm.17-0037. Epub 2017 Jun 27.
4
Leukotriene B antagonism ameliorates experimental lymphedema.白三烯 B 拮抗作用改善实验性淋巴水肿。
Sci Transl Med. 2017 May 10;9(389). doi: 10.1126/scitranslmed.aal3920.
5
Adipose-Derived Stem Cells and Vascularized Lymph Node Transfers Successfully Treat Mouse Hindlimb Secondary Lymphedema by Early Reconnection of the Lymphatic System and Lymphangiogenesis.脂肪来源干细胞和带血管蒂淋巴结转移通过早期重建淋巴系统和淋巴管生成成功治疗小鼠后肢继发性淋巴水肿
Plast Reconstr Surg. 2017 Mar;139(3):639-651. doi: 10.1097/PRS.0000000000003110.
6
The pro-inflammatory cytokine TNF-α inhibits lymphatic pumping via activation of the NF-κB-iNOS signaling pathway.促炎细胞因子肿瘤坏死因子-α通过激活核因子κB-诱导型一氧化氮合酶信号通路抑制淋巴泵功能。
Microcirculation. 2017 Apr;24(3). doi: 10.1111/micc.12364.
7
Topical tacrolimus for the treatment of secondary lymphedema.局部他克莫司治疗继发性淋巴水肿。
Nat Commun. 2017 Feb 10;8:14345. doi: 10.1038/ncomms14345.
8
Inflammatory Manifestations of Lymphedema.淋巴水肿的炎症表现
Int J Mol Sci. 2017 Jan 17;18(1):171. doi: 10.3390/ijms18010171.
9
Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis.放射治疗靶点与乳腺癌相关淋巴水肿的风险：一项系统评价与网状Meta分析
Breast Cancer Res Treat. 2017 Apr;162(2):201-215. doi: 10.1007/s10549-016-4089-0. Epub 2016 Dec 23.
10
Regulatory T cell transfer ameliorates lymphedema and promotes lymphatic vessel function.调节性 T 细胞转移可改善淋巴水肿并促进淋巴管功能。
JCI Insight. 2016 Oct 6;1(16):e89081. doi: 10.1172/jci.insight.89081.
Zotero 插件